InterShunt Technologies, an early-stage medical device company developing a novel catheter-based solution to reduce left atrial pressure in heart failure patients, announced the completion of an equity financing. The round was led by Solas BioVentures with participation from Arsenal Capital Management and a select group of industry executives.

InterShunt is developing a proprietary catheter system that allows for the capture and excision of tissue from the interatrial septum. The result is a left to right atrial shunt that off-loads elevated left atrial pressure, reducing symptoms in Heart Failure patients. The mechanical system is designed for safety and ease of use and is the only interatrial shunting device that requires no implant and no energy.